Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections-proceedings and data from the gram-negative resistance summit

Clinical Infectious Diseases

Volumn 53, Issue SUPPL. 2, 2011, Pages

  Kollef, Marin H ^a   Golan, Yoav ^b   Micek, Scott T ^c   Shorr, Andrew F ^d,e   Restrepo, Marcos I ^f,g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; PROCALCITONIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG POTENTIATION; ENTEROCOCCUS FAECIUM; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HORMONE BLOOD LEVEL; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; LENGTH OF STAY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PERITONITIS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK; TREATMENT DURATION; TREATMENT RESPONSE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 80052221556     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir475     Document Type: Article

References (92)

1. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
3. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68. (Pubitemid 43271379)
4. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45:1179-81. (Pubitemid 47580316)
5. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007; 45:88-94. (Pubitemid 46984623)
6. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597-602.
7. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century: a clinical super-challenge. N Engl J Med 2009; 360:439-43.
8. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008; 47(Suppl 1):S3-13.
9. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31(Suppl 4):S131-8. (Pubitemid 32291120)
10. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-11. (Pubitemid 40463352)
11. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55. (Pubitemid 30485502)
12. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:2742-51. (Pubitemid 38010630)
13. Dhainaut JF, Laterre PF, LaRosa SP, et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 2003; 31:2291-301.
14. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180:861-6.
15. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-35. (Pubitemid 37352798)
16. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327.
17. Paterson DL, Rogers BA. How soon is now? The urgent need for randomized, controlled trials evaluating treatment of multidrug-resistant bacterial infection. Clin Infect Dis 2010; 51:1245-7.
18. Christoff J, Tolentino J, Mawdsley E, Matushek S, Pitrak D, Weber SG. Optimizing empirical antimicrobial therapy for infection due to gram-negative pathogens in the intensive care unit: utility of a combination antibiogram. Infect Control Hosp Epidemiol 2010; 31:256-61.
19. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74. (Pubitemid 29083057)
20. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96. (Pubitemid 43810035)
21. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010; 54:1742-8.
22. Al-Hasan MN, Wilson JW, Lahr BD, et al. Beta-lactam and fluo-roquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli. Antimicrob Agents Chemother 2009; 53: 1386-94.
23. Heyland DK, Dodek P, Muscedere J, Day A, Cook D. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36:737-44.
24. Chaudhary M, Shrivastava SM, Varughese L, Sehgal R. Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. Curr Clin Pharmacol 2008; 3:118-22.
25. Magnotti LJ, Schroeppel TJ, Clement LP, et al. Efficacy of monotherapy in the treatment of Pseudomonas ventilator-associated pneumonia in patients with trauma. J Trauma 2009; 66:1052-8discussion 1058-59.
26. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bac-teremia. Antimicrob Agents Chemother 2003; 47:2756-64. (Pubitemid 37040244)
27. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Anti-microb Agents Chemother 1994; 38:1309-13. (Pubitemid 24170712)
28. Solberg CO, Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 1995; 36(Suppl A):157-66.
29. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; (1);CD003344.
30. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38:1773-85.
31. Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 2008; 168:2254-60.
32. Kollef MH, Napolitano LM, Solomkin JS, et al. Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit. Clin Infect Dis 2008; 47(Suppl 2):S55-99; quiz S100-1.
33. Kollef MH, Morrow LE, Baughman RP, et al. Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes: proceedings of the HCAP Summit. Clin Infect Dis 2008; 46(Suppl 4):S296-334; quiz 335-8. (Pubitemid 351590141)
34. Bhat SV, Peleg AY, Lodise TP Jr, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007; 51:4390-5. (Pubitemid 350209894)
35. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008; 46:862-7. (Pubitemid 351417187)
36. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T.MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31:345-51.
37. CLSI M100-S20 (2010) cephalosporin and aztreonam breakpoint revisions fact sheet. Clinical and Laboratory Standards Institute. Available at: http://www.clsi.org/Content/NavigationMenu/Committees/Microbiology/AST/ CephalosporinandAztreonamBreakpointRevision FactSheet/ CephalosporinAztreonamBreakpointFactSheet.pdf. Accessed 26 July 2011.
38. Cockerill III FR, Wikler MA, Bush K. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement (June 2010 update). Clinical and Laboratory Standards Institute. Available at: http://www.clsi.org/source/orders/free/m100-s20-u.pdf. Published 1 June 2010. Accessed 26 July 2011.
39. Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmaco-kinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009; 53:1476-81.
40. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. Pharmacokinetic- pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009; 63:409-14.
41. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35:156-63.
42. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40: 219-23. (Pubitemid 43269850)
43. Lorente L, Jimenez A, Palmero S, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007; 29:2433-9. (Pubitemid 350298123)
44. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piper-acillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009; 33:464-8.
45. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357-63. (Pubitemid 46147617)
46. Patel GW, Patel N, Lat A, et al. Outcomes of extended infusion pi-peracillin/tazobactam for documented gram-negative infections. Diagn Microbiol Infect Dis 2009; 64:236-40.
47. Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010; 25:69-77.
48. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009; 37:2071-8.
49. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imi-penem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089-96. (Pubitemid 351482655)
50. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-53. (Pubitemid 41817713)
51. Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008; 36:108-17.
52. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668.
53. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta- regression study. Crit Care Med 2010; 38:1651-64.
54. Schentag JJ, Strenkoski-Nix LC, Nix DE, Forrest A. Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis 1998; 27:40-6. (Pubitemid 28334416)
55. Maragakis LL. Recognition and prevention of multidrug-resistant gram-negative bacteria in the intensive care unit. Crit Care Med 2010; 38(Suppl 8):S345-51.
56. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-32. (Pubitemid 29230866)
57. George P, Morris AM. Pro/con debate: should antimicrobial stewardship programs be adopted universally in the intensive care unit? Crit Care 2010; 14:205.
58. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163:1371-5. (Pubitemid 32506601)
59. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-11. (Pubitemid 30647191)
60. Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. Clin Infect Dis 2010; 51(Suppl 1):S131-5.
61. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-15. (Pubitemid 32554320)
62. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-98. (Pubitemid 37443289)
63. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34:1364-75.
64. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375: 463-74.
65. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010; 38:1-13.
66. Donaldson AD, Razak L, Liang LJ, Fisher DA, Tambyah PA. Car-bapenems and subsequent multiresistant bloodstream infection: does treatment duration matter? Int J Antimicrob Agents 2009; 34:246-51.
67. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-49.
68. D'Agata EM, Magal P, Olivier D, Ruan S, Webb GF. Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration. J Theor Biol 2007; 249:487-99. (Pubitemid 350046634)
69. Dancer SJ. The effect of antibiotics on methicillin-resistant Staphylo-coccus aureus. J Antimicrob Chemother 2008; 61:246-53.
70. Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit: advances and obstacles. Am J Respir Crit Care Med 2009; 179:434-8.
71. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298-314. (Pubitemid 32163954)
72. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9.
73. Nseir S, Grailles G, Soury-Lavergne A, Minacori F, Alves I, Durocher A. Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with mul-tidrug resistant bacteria at intensive-care unit admission. Clin Micro-biol Infect 2010; 16:902-8.
74. Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104:1230-5. (Pubitemid 23306084)
75. Bukholm G, Tannaes T, Kjelsberg AB, Smith-Erichsen N. An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect Control Hosp Epidemiol 2002; 23:441-6.
76. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999; 159:1249-56. (Pubitemid 29202563)
77. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-20. (Pubitemid 28110020)
78. Yakupogullari Y, Otlu B, Dogukan M, et al. Investigation of a noso-comial outbreak by alginate-producing pan-antibiotic-resistant Pseu-domonas aeruginosa. Am J Infect Control 2008; 36:e13-8.
79. Rodriguez-Bano J, Garcia L, Ramirez E, et al. Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach. Am J Infect Control 2009; 37:715-22.
80. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Saroglou G, Geroulanos S. Preventing strategy of multidrug-resistant Acinetobacter baumanii susceptible only to colistin in cardiac surgical intensive care units. Eur J Cardiothorac Surg 2008; 33:1086-90.
81. Marchaim D, Navon-Venezia S, Schwartz D, et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter bau-mannii. J Clin Microbiol 2007; 45:1551-5. (Pubitemid 46762412)
82. Apisarnthanarak A, Pinitchai U, Thongphubeth K, Yuekyen C, Warren DK, Fraser VJ. A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study. Clin Infect Dis 2008; 47:760-7.
83. Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009; 30:447-52.
84. Souweine B, Traore O, Aublet-Cuvelier B, et al. Role of infection control measures in limiting morbidity associated with multi-resistant organisms in critically ill patients. J Hosp Infect 2000; 45:107-16. (Pubitemid 30438974)
85. Albertini MT, Benoit C, Berardi L, et al. Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study. J Hosp Infect 2002; 52: 107-13. (Pubitemid 38001940)
86. Munoz-Price LS, Hayden MK, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010; 31:341-7.
87. Kola A, Holst M, Chaberny IF, Ziesing S, Suerbaum S, Gastmeier P. Surveillance of extended-spectrum beta-lactamase-producing bacteria and routine use of contact isolation: experience from a three-year period. J Hosp Infect 2007; 66:46-51. (Pubitemid 46657123)
88. Gardam MA, Burrows LL, Kus JV, et al. Is surveillance for multidrug-resistant Enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis 2002; 186:1754-60. (Pubitemid 35463508)
89. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008; 299: 1149-57. (Pubitemid 351398429)
90. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148:409-18. (Pubitemid 351665440)
91. Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase: United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:750.
92. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77. (Pubitemid 46084814)